Clinical trial
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic)…
NCT00415532 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00415532 |
|---|---|
| Title | Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura |
| Official title | A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenic Purpura |
| Intervention type | Biological, Drug |
| Interventions | Medical Standard of Care for ITP, Romiplostim |
| Enrollment | 234 |
| Start date | Dec 1, 2006 |
| Primary completion | Nov 7, 2008 |
| Completion | May 11, 2009 |
| First posted | Dec 25, 2006 |
| Last update posted | Nov 8, 2022 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: